<p>Adherex Technologies Inc.（纳斯达克代码：FENC - 获取免费报告）董事 Rosty Raykov 于 2 月 2 日星期一出售了 10,349 股该公司的股票。股票以平均价格 7.76 美元出售，总交易额为 80,308.24 美元。交易后，该董事直接持有 98,477 股公司的股票，价值 764,181.52 美元。这代表其持股比例下降了 9.51%。该交易已在与美国证券交易委员会（SEC）的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
<p>获取 <strong>Adherex Technologies</strong> 的提醒：</p>
<p>Rosty Raykov 最近还进行了以下交易：</p>
<ul>
<li>在 12 月 5 日星期五，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均价格 7.54 美元出售，总价值为 75,400.00 美元。</li>
<li>在 11 月 5 日星期三，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均价格 8.10 美元出售，总价值为 81,000.00 美元。</li>
</ul>
<h2>Adherex Technologies 股票上涨 3.2%</h2>
<p>在周一的午盘交易中，纳斯达克 FENC 的股票上涨了 0.24 美元，达到了 7.83 美元。该股票的交易量为 134,027 股，较其平均交易量 116,975 股有所增加。该公司的市值为 2.675 亿美元，市盈率为-34.04，贝塔值为 0.78。该公司 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 8.28 美元。Adherex Technologies Inc.的 12 个月低点为 4.68 美元，12 个月高点为 9.92 美元。</p>
<p>Adherex Technologies（纳斯达克代码：FENC - 获取免费报告）最近一次发布财报是在 11 月 13 日星期四。公司报告本季度每股收益（EPS）为-0.02 美元，超出市场共识预期的-0.08 美元，超出幅度为 0.06 美元。该季度的收入为 1246 万美元，而分析师预期为 1343 万美元。研究分析师预计 Adherex Technologies Inc.在当前财政年度将发布-0.11 的每股收益。</p>
<h2>对 Adherex Technologies 的对冲基金看法</h2>
<p>一家机构投资者最近在 Adherex Technologies 股票中建立了新头寸。根据其最近向证券交易委员会提交的文件，Jane Street Group LLC 在第一季度购买了 Adherex Technologies Inc.（纳斯达克代码：FENC - 免费报告）的新股份。该基金购买了 14,718 股公司的股票，价值约 90,000 美元。Jane Street Group LLC 在最近的报告期末持有 Adherex Technologies 约 0.05% 的股份。55.51% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>分析师升级和降级</h2>
<p>几位股票分析师对 FENC 股票发布了报告。Weiss Ratings 在 1 月 22 日星期四的研究报告中重申了对 Adherex Technologies 股票的 “卖出（d-）” 评级。Wall Street Zen 在 1 月 17 日星期六的研究报告中将 Adherex Technologies 的股票评级从 “强买” 下调至 “买入”。Zacks Research 在 12 月 12 日星期五的报告中将 Adherex Technologies 的评级从 “强卖” 上调至 “持有”。最后，Piper Sandler 在 1 月 9 日星期五的报告中开始覆盖 Adherex Technologies。他们给予该公司的 “增持” 评级，并设定了 18.00 美元的目标价格。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Adherex Technologies 目前的共识评级为 “适度买入”，共识目标价格为 14.50 美元。</p>
<p><strong>查看我们最新的 FENC 研究报告</strong></p>
<h2>关于 Adherex Technologies</h2>
<p>（获取免费报告）</p>
<p>Fennec Pharmaceuticals Inc.是一家生物制药公司，开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防顺铂引起的儿童听力损失或耳毒性的 III 期临床试验。该公司曾名为 Adherex Technologies Inc.，并于 2014 年 9 月更名为 Fennec Pharmaceuticals Inc.。Fennec Pharmaceuticals Inc.成立于 1996 年，总部位于北卡罗来纳州的研究三角园。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Adherex Technologies 更好</li>
<li>巨大的黄金预测</li>
<li>黄金的反弹很大——但接下来可能会更大</li>
<li>美国的终结更新</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>华尔街害怕的黄金图表…</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Adherex Technologies 吗？</h2>
<p>在考虑 Adherex Technologies 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Adherex Technologies 并不在名单上。</p>
<p>虽然 Adherex Technologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

FENC

<p>Adherex Technologies Inc.（纳斯达克代码：FENC）董事 Rosty Raykov 以平均价格 7.76 美元出售了 10,349 股，总计 80,308.24 美元，持股比例减少了 9.51%。交易后，他持有 98,477 股，价值约 764,181.52 美元。该股票在午盘交易中上涨了 3.2%，至 7.83 美元。分析师对该股票的评级意见不一，普遍评级为 “适度买入”，目标价格为 14.50 美元。该公司专注于癌症治疗，曾名为 Adherex Technologies，并于 2014 年更名为 Fennec Pharmaceuticals</p>

<p>Adherex Technologies Inc. (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,349 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $7.76, for a total transaction of $80,308.24. Following the transaction, the director directly owned 98,477 shares of the company's stock, valued at $764,181.52. This represents a 9.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.</p>
<div class="lb-trans"><p>Adherex Technologies Inc.（纳斯达克代码：FENC - 获取免费报告）董事 Rosty Raykov 于 2 月 2 日星期一出售了 10,349 股该公司的股票。股票以平均价格 7.76 美元出售，总交易额为 80,308.24 美元。交易后，该董事直接持有 98,477 股公司的股票，价值 764,181.52 美元。这代表其持股比例下降了 9.51%。该交易已在与美国证券交易委员会（SEC）的法律文件中披露，相关信息可通过 SEC 网站获取。</p>
</div><p>Get <strong>Adherex Technologies</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Adherex Technologies</strong> 的提醒：</p>
</div><p>Rosty Raykov also recently made the following trade(s):</p>
<div class="lb-trans"><p>Rosty Raykov 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, December 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The stock was sold at an average price of $7.54, for a total value of $75,400.00.</li>
<li>On Wednesday, November 5th, Rosty Raykov sold 10,000 shares of Adherex Technologies stock. The shares were sold at an average price of $8.10, for a total value of $81,000.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 12 月 5 日星期五，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均价格 7.54 美元出售，总价值为 75,400.00 美元。</li>
<li>在 11 月 5 日星期三，Rosty Raykov 出售了 10,000 股 Adherex Technologies 的股票。股票以平均价格 8.10 美元出售，总价值为 81,000.00 美元。</li>
</ul>
</div><h2>Adherex Technologies Stock Up 3.2%</h2>
<div class="lb-trans"><h2>Adherex Technologies 股票上涨 3.2%</h2>
</div><p>Shares of NASDAQ FENC traded up $0.24 during midday trading on Monday, reaching $7.83. 134,027 shares of the stock were exchanged, compared to its average volume of 116,975. The firm has a market cap of $267.50 million, a price-to-earnings ratio of -34.04 and a beta of 0.78. The firm has a 50-day simple moving average of $7.66 and a two-hundred day simple moving average of $8.28. Adherex Technologies Inc. has a twelve month low of $4.68 and a twelve month high of $9.92.</p>
<div class="lb-trans"><p>在周一的午盘交易中，纳斯达克 FENC 的股票上涨了 0.24 美元，达到了 7.83 美元。该股票的交易量为 134,027 股，较其平均交易量 116,975 股有所增加。该公司的市值为 2.675 亿美元，市盈率为-34.04，贝塔值为 0.78。该公司 50 日简单移动平均线为 7.66 美元，200 日简单移动平均线为 8.28 美元。Adherex Technologies Inc.的 12 个月低点为 4.68 美元，12 个月高点为 9.92 美元。</p>
</div><p>Adherex Technologies (NASDAQ:FENC - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.06. The firm had revenue of $12.46 million during the quarter, compared to analyst estimates of $13.43 million. Research analysts expect that Adherex Technologies Inc. will post -0.11 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Adherex Technologies（纳斯达克代码：FENC - 获取免费报告）最近一次发布财报是在 11 月 13 日星期四。公司报告本季度每股收益（EPS）为-0.02 美元，超出市场共识预期的-0.08 美元，超出幅度为 0.06 美元。该季度的收入为 1246 万美元，而分析师预期为 1343 万美元。研究分析师预计 Adherex Technologies Inc.在当前财政年度将发布-0.11 的每股收益。</p>
</div><h2>Hedge Funds Weigh In On Adherex Technologies</h2>
<div class="lb-trans"><h2>对 Adherex Technologies 的对冲基金看法</h2>
</div><p>An institutional investor recently bought a new position in Adherex Technologies stock. Jane Street Group LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 14,718 shares of the company's stock, valued at approximately $90,000. Jane Street Group LLC owned about 0.05% of Adherex Technologies at the end of the most recent reporting period. 55.51% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Adherex Technologies 股票中建立了新头寸。根据其最近向证券交易委员会提交的文件，Jane Street Group LLC 在第一季度购买了 Adherex Technologies Inc.（纳斯达克代码：FENC - 免费报告）的新股份。该基金购买了 14,718 股公司的股票，价值约 90,000 美元。Jane Street Group LLC 在最近的报告期末持有 Adherex Technologies 约 0.05% 的股份。55.51% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析师升级和降级</h2>
</div><p>Several equities analysts have issued reports on FENC shares. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adherex Technologies in a research report on Thursday, January 22nd. Wall Street Zen lowered shares of Adherex Technologies from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, January 17th. Zacks Research upgraded Adherex Technologies from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Friday, December 12th. Finally, Piper Sandler assumed coverage on Adherex Technologies in a report on Friday, January 9th. They set an &#34;overweight&#34; rating and a $18.00 target price for the company. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Adherex Technologies presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $14.50.</p>
<div class="lb-trans"><p>几位股票分析师对 FENC 股票发布了报告。Weiss Ratings 在 1 月 22 日星期四的研究报告中重申了对 Adherex Technologies 股票的 “卖出（d-）” 评级。Wall Street Zen 在 1 月 17 日星期六的研究报告中将 Adherex Technologies 的股票评级从 “强买” 下调至 “买入”。Zacks Research 在 12 月 12 日星期五的报告中将 Adherex Technologies 的评级从 “强卖” 上调至 “持有”。最后，Piper Sandler 在 1 月 9 日星期五的报告中开始覆盖 Adherex Technologies。他们给予该公司的 “增持” 评级，并设定了 18.00 美元的目标价格。四位投资分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，Adherex Technologies 目前的共识评级为 “适度买入”，共识目标价格为 14.50 美元。</p>
</div><p><strong>View Our Latest Research Report on FENC</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 FENC 研究报告</strong></p>
</div><h2>About Adherex Technologies</h2>
<div class="lb-trans"><h2>关于 Adherex Technologies</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals Inc.是一家生物制药公司，开发用于治疗美国癌症的产品候选药物。其主要产品候选药物是硫代硫酸钠，已完成用于预防顺铂引起的儿童听力损失或耳毒性的 III 期临床试验。该公司曾名为 Adherex Technologies Inc.，并于 2014 年 9 月更名为 Fennec Pharmaceuticals Inc.。Fennec Pharmaceuticals Inc.成立于 1996 年，总部位于北卡罗来纳州的研究三角园。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Adherex Technologies</li>
<li>HUGE gold prediction</li>
<li>Gold’s rally is big — but what comes next could be bigger</li>
<li>End of America Update</li>
<li>Trump’s Final Shocking Act Begins February 24</li>
<li>The gold chart Wall Street is terrified of…</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Adherex Technologies 更好</li>
<li>巨大的黄金预测</li>
<li>黄金的反弹很大——但接下来可能会更大</li>
<li>美国的终结更新</li>
<li>特朗普的最后震惊行动将于 2 月 24 日开始</li>
<li>华尔街害怕的黄金图表…</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RkVOQw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=FENC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Adherex Technologies Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Adherex Technologies 吗？</h2>
</div><p>Before you consider Adherex Technologies, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Adherex Technologies 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adherex Technologies wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Adherex Technologies 并不在名单上。</p>
</div><p>While Adherex Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Adherex Technologies 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内部人士出售：Adherex Technologies（NASDAQ:FENC）的一位董事出售了 10,349 股股票